Story

NeOnc Technologies Surges on Positive Phase 2a Brain Cancer Trial Data

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
NeOnc Technologies Surges on Positive Phase 2a Brain Cancer Trial Data
Text size
Background

NeOnc Technologies (NTHI) shares surged in pre-market trading after the biopharmaceutical company announced that its Phase 2a trial for an experimental brain cancer therapy successfully met its primary endpoint. The positive data, a critical milestone for the company, prompted a brief halt in the stock's trading pending the news.

Key Trial Data

The NEO100-01 trial evaluated the drug in 24 patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma, a difficult-to-treat form of brain cancer. According to the company's announcement during an investor call, the study reported a six-month progression-free survival rate of 48.9%.

This result significantly surpassed the pre-specified benchmark of 20%, achieving a high degree of statistical significance with a p-value of 0.0047. The company noted that all patients in the open-label study had previously failed standard-of-care treatments, including radiation and temozolomide.

Market Reaction and Technical Factors

Investors reacted strongly to the news, sending the stock up 12.4% in pre-open trading. The outsized move was amplified by several technical and market factors that created a volatile setup heading into the data release.

Sample IUX Markets – In-articleAd

According to market data cited by Investing.com, several conditions contributed to the sharp rally:

  • High short interest, with more than 500,000 shares held by short-sellers, made the stock susceptible to a short squeeze on positive news.
  • The stock was trading near its 52-week low before the announcement, suggesting compressed valuations.
  • Significant insider buying was previously reported, with the Chairman and CEO purchasing over $500,000 in shares on the open market over the past year.

Context and Outlook

While the broader market was modestly positive on the day, the clinical trial catalyst was the dominant driver for NeOnc Technologies. The company described the results as one of the most important clinical milestones in its history.

The successful Phase 2a readout positions NEO100 for potential future regulatory discussions and further clinical development, representing a significant step forward for the company's lead asset.

Read next

More on Stocks
Back to latest news

LATEST